DDResponse is a Collaborative Project funded by the 7th Framework Programme of the European Commission in the theme Health. The start date of the project is 1 February 2011. It will end on 31 January 2015.
For the intro movie on the project click here.
One of the most important developments in biomedical genetics over the last decade is the realisation that preservation of genetic integrity mediated by the DNA damage response (DDR) is both of enormous fundamental and medical importance. This holds most notably for cancer and many aging-related diseases, which have strong connections with DNA damage and genome maintenance.
As these diseases represent the main causes of mortality and morbidity in many countries world-wide, this 'DDResponse' proposal directly addresses the prevailing medical needs of all modern societies.
The principal objective of this collaborative project is to unlock the full potential of genome maintenance / DNA damage response (DDR) mechanisms to derive new therapies, assess individual susceptibility and predict individual responses to anti-cancer therapies that exploit DDR deficiencies, which appear universal in most, if not all, cancers. The proposal focuses on, but is not limited to, breast cancer.